AstraZeneca, Kyowa Hakko Kirin deal

AstraZeneca granted Kyowa’s ProStrakan Group plc subsidiary exclusive rights to develop and commercialize Moventig naloxegol in the EU, Iceland, Norway, Switzerland and Liechtenstein. AZ has exclusive, worldwide rights to the PEGylated form of naloxol, a peripheral mu opioid receptor ( OPRM1; MOR) antagonist, from Nektar Therapeutics (NASDAQ:NKTR, San Francisco, Calif.). ...